journal
Journals Japanese Journal of Clinical O...

Japanese Journal of Clinical Oncology

https://read.qxmd.com/read/39023445/methotrexate-associated-lymphoproliferative-disorder-of-the-heart
#1
JOURNAL ARTICLE
Toshiyuki Sumi, Keito Suzuki, Kotomi Arioka, Hirofumi Chiba
No abstract text is available yet for this article.
July 18, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/39023439/high-cost-of-chemotherapy-for-gynecologic-malignancies
#2
JOURNAL ARTICLE
Nobutaka Takahashi, Toshiyuki Seki, Keita Sasaki, Ryunosuke Machida, Mitsuya Ishikawa, Mayu Yunokawa, Ayumu Matsuoka, Masahiro Kagabu, Satoshi Yamaguchi, Kengo Hiranuma, Junki Ohnishi, Toyomi Sato
BACKGROUND: The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care. METHODS: The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens. RESULTS: A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies...
July 18, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38970830/soft-tissue-sarcoma-in-japan-national-cancer-registry-based-analysis-from-2016-to-2019
#3
JOURNAL ARTICLE
Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Yoko Katoh, Takahiro Higashi, Akira Kawai
BACKGROUND: No previous reports have characterized national profiles of soft-tissue sarcoma overall. We examined the nationwide statistics for soft-tissue sarcoma in Japan using data from the population-based National Cancer Registry. METHODS: We identified 23 522 soft-tissue-sarcoma patients who were entered in the National Cancer Registry during 2016-19 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology...
July 7, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38960402/diagnosis-of-glioma-recurrence-using-18f-fapi-04-and-18f-psma-1007-pet-ct
#4
JOURNAL ARTICLE
Jingyu Fu, Daiyun Peng, Ying Zhang, Jiangyan Liu
No abstract text is available yet for this article.
July 3, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38943560/association-of-the-modified-glasgow-prognostic-score-and-prognostic-nutritional-index-with-duration-of-oral-anamorelin-administration-in-patients-with-cancer-cachexia-a-retrospective-cohort-study
#5
JOURNAL ARTICLE
Kazuma Fujita, Yumiko Akamine, Haruka Igarashi, Yayoi Fukushi, Katsuya Sasaki, Koji Fukuda, Masafumi Kikuchi, Hiroyuki Shibata
BACKGROUND: The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin...
June 29, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38943559/association-between-response-to-enfortumab-vedotin-and-peripheral-neuropathy-in-urothelial-carcinoma-patients-a-multicenter-retrospective-study
#6
JOURNAL ARTICLE
Nozomi Hayakawa, Eiji Kikuchi, Go Kaneko, Ryo Yamashita, Daiki Ikarashi, Yuki Endo, Kimitsugu Usui, Wataru Obara, Masafumi Oyama, Yukihiro Kondo
BACKGROUND: Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated. METHODS: We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV...
June 29, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38943456/assessing-alimentary-tract-radiation-in-liver-cancer-treatment-with-proton-beam-therapy-a-pet-ct-imaging-study
#7
JOURNAL ARTICLE
Sachika Shiraishi, Masashi Yamanaka, Shintaro Shiba, Koichi Tokuuye
BACKGROUND: Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer. METHODS: In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients...
June 29, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38941345/protocol-digest-of-a-randomized-phase-iii-trial-comparing-s-1-based-chemoradiotherapy-with-without-nivolumab-for-unresectable-locally-advanced-or-borderline-resectable-pancreatic-cancer-jcog1908e-penetrate
#8
JOURNAL ARTICLE
Yusuke Sano, Masashi Kanai, Chigusa Morizane, Keita Sasaki, Michio Yoshimura, Yoshinori Ito, Junji Furuse, Masato Ozaka, Haruhiko Fukuda, Makoto Ueno
Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer, but its efficacy is not sufficient. Induction of the synergistic effect of irradiation and immune checkpoint inhibitors can be an attractive strategy. An open-label randomized phase III trial has been conducted since October 2020 to confirm the superiority of nivolumab plus S-1-based chemoradiotherapy over S-1-based chemoradiotherapy alone in patients with UR-LA or BR pancreatic cancer...
June 28, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38941323/sarcopenic-obesity-predicts-short-and-long-term-outcomes-after-neoadjuvant-chemotherapy-and-surgery-for-gastric-cancer
#9
JOURNAL ARTICLE
Chunning Duan, Mingru Wu, Xia Wen, Lvping Zhuang, Jianwei Sun
BACKGROUND: Sarcopenic obesity (SO) affects outcomes in various malignancies. However, its clinical significance in patients undergoing neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) remains unclear. This study investigated the impact of pre- and post-NAC SO on postoperative morbidity and survival. METHODS: Data from 207 patients with LAGC, who underwent NAC followed by radical gastrectomy between January 2010 and October 2019, were reviewed...
June 28, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38920339/associations-between-early-changes-in-the-neutrophil-to-lymphocyte-ratio-after-radical-nephroureterectomy-and-treatment-outcomes
#10
JOURNAL ARTICLE
Shun Saito, Hidetsugu Takahashi, Yuji Yata, Shigeyoshi Takamizawa, Shuhei Hara, Keiichiro Miyajima, Kosuke Iwatani, Keiji Yasue, Hideomi Nishikawa, Toshihiro Yamamoto, Haruhisa Koide, Ibuki Sadakane, Mahito Atsuta, Keiichiro Mori, Yu Imai, Sotaro Kayano, Masaya Murakami, Kojiro Tashiro, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Fumihiko Urabe, Takahiro Kimura, On Behalf Of Jikei-Scrum Collaborative Group
OBJECTIVES: This study explored the impacts of peri-operative changes in the neutrophil-to-lymphocyte ratio (NLR) on the survival rate after radical nephroureterectomy. METHODS: This retrospective analysis included a multicentric cohort of patients diagnosed with upper tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy from 2012 to 2021. We assessed the preoperative NLR, postoperative NLR, delta-NLR (difference between postoperative and preoperative NLRs), and NLR change (ratio of postoperative to preoperative NLR)...
June 26, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38899830/projection-of-the-number-of-new-cases-of-thyroid-cancer-in-the-world
#11
JOURNAL ARTICLE
Tomohiro Matsuda, Sumiyo Okawa
No abstract text is available yet for this article.
June 20, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38884136/changes-in-the-trends-of-initial-treatment-for-newly-diagnosed-prostate-cancer-in-japan-a-nationwide-multi-institutional-study
#12
JOURNAL ARTICLE
Taketo Kawai, Mizuki Onozawa, Satoru Taguchi, Masaki Shiota, Shinichi Sakamoto, Yoshiyuki Yamamoto, Yasuhide Kitagawa, Tohru Nakagawa, Shiro Hinotsu, Haruki Kume
BACKGROUND: In previous large-scale studies conducted through 2010, androgen deprivation therapy (ADT) was the most common initial treatment for prostate cancer patients in Japan. However, recent advancements in treatment technologies have significantly affected the management of prostate cancer in Japan. This study analyzed the trends in initial treatments for prostate cancer based on two nationwide surveys. METHODS: Two Japan-wide multi-institutional surveys, J-CaP2010 and J-CaP2016, were conducted to enroll patients newly histologically diagnosed with prostate cancer in 2010 and 2016-18, respectively...
June 17, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38884134/analysis-of-pik3ca-mutations-in-the-primary-and-recurrent-tumors-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#13
JOURNAL ARTICLE
Yue Wang, Xin Li, Shuang Zhang, Li Liang, Ling Xu, Yinhua Liu, Ting Li
OBJECTIVE: Our aim was to compare the PIK3CA mutation status in matched primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) to gain insight into the optimization of patient selection and detection time for PIK3CA-targeted therapy. METHODS: The data were from 3035 patients with BC diagnosed at the Breast Disease Center, Peking University First Hospital, between January 2008 and December 2017...
June 17, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38881250/correction-to-current-status-of-the-cost-burden-of-first-line-systemic-treatment-for-patients-with-advanced-hepatocellular-carcinoma-in-japan-2021-22
#14
(no author information available yet)
No abstract text is available yet for this article.
June 17, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38864253/franseen-needle-in-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-a-phase-ii-prospective-study
#15
JOURNAL ARTICLE
Kohei Shikano, Jun Ikari, Takahiro Nakajima, Masayuki Ota, Yuki Shiko, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Jun-Ichiro Ikeda, Yoshihito Ozawa, Takuji Suzuki
BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been used to diagnose and stage lung cancer. Acquire™ Pulmonary and Expect™ Pulmonary dedicated EBUS-TBNA needles were introduced as the Franseen and Lancet needles, respectively. It is still unclear whether the Franseen or Lancet needles yield a higher quality specimen especially focusing on next-generation sequencing-based molecular testing. METHODS: A single-center, prospective study performed at the Chiba University Hospital randomly assigned patients to two groups: Group A, wherein the first and second EBUS-TBNA were performed using Lancet and Franseen needles, respectively, and Group B, wherein the first and second EBUS-TBNA were performed using Franseen and Lancet needles, respectively...
June 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38864246/evaluation-of-pet-ct-imaging-with-89zr-zr-dfo-girentuximab-a-phase-1-clinical-study-in-japanese-patients-with-renal-cell-carcinoma-zirdac-jp
#16
JOURNAL ARTICLE
Noboru Nakaigawa, Hisashi Hasumi, Daisuke Utsunomiya, Keisuke Yoshida, Yoshinobu Ishiwata, Takashi Oka, Colin Hayward, Kazuhide Makiyama
BACKGROUND: PET/CT imaging with Zirconium-89 labeled [89Zr]Zr-DFO-girentuximab, which targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell renal cell carcinomas (RCC) and other renal and extrarenal lesions, and has been studied in European and American cohorts. We report results from a phase I study that evaluated the safety profile, biodistribution, and dosimetry of [89Zr]Zr-DFO-girentuximab in Japanese patients with suspected RCC. METHODS: Eligible adult patients received 37 MBq (± 10%; 10 mg mass dose) of intravenous [89Zr]Zr-DFO-girentuximab...
June 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38864243/a-nomogram-to-predict-the-pathological-complete-response-in-patients-with-breast-cancer-based-on-the-tils-us-score
#17
JOURNAL ARTICLE
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada
BACKGROUND: The tumor-infiltrating lymphocytes-ultrasonography score is a calculation system for predicting lymphocyte-predominant breast cancers in surgical specimens. A nomogram based on the tumor-infiltrating lymphocytes-ultrasonography score was developed to predict the pathological complete response in breast cancer treated with neoadjuvant chemotherapy. METHODS: A retrospective evaluation was conducted on 118 patients with breast cancer treated with neoadjuvant chemotherapy at Hiroshima University Hospital...
June 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38864223/factors-associated-with-work-sustainability-in-patients-with-bone-metastasis
#18
JOURNAL ARTICLE
Ryoko Sawada, Yusuke Shinoda, Takahiro Ohki, Yuki Ishibashi, Hiroshi Kobayashi, Sakae Tanaka, Nobuhiko Haga
BACKGROUND: Working while receiving cancer treatment is challenging for patients, with considerable impact on their quality of life (QOL). However, there have been no reports on the factors that prevent employment in patients with bone metastases. This study aimed to investigate the employment status and factors impacting the continued employment of patients with bone metastases. METHODS: We analyzed clinical data from new patients consulting The University of Tokyo Hospital team for bone metastasis treatment between June 2015 and September 2017...
June 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38843879/current-status-of-the-cost-burden-of-first-line-systemic-treatment-for-patients-with-advanced-hepatocellular-carcinoma-in-japan-2021-22
#19
JOURNAL ARTICLE
Hiroshi Imaoka, Keita Sasaki, Ryunosuke Machida, Hiroaki Nagano, Sohei Satoi, Masafumi Ikeda, Satoshi Kobayashi, Taro Yamashita, Takuji Okusaka, Akio Ido, Etsuro Hatano, Haruo Miwa, Masaki Ueno, Kazuhiko Nakao, Satoshi Shimizu, Hidekazu Kuramochi, Ryotaro Sakamori, Hidetaka Tsumura, Naohiro Okano, Kazuhiko Shioji, Hirofumi Shirakawa, Noriyuki Akutsu, Kunihiro Tsuji, Hiroshi Ishii, Kumiko Umemoto, Akinori Asagi, Makoto Ueno
BACKGROUND: Although recent advances in systemic therapies for hepatocellular carcinoma (HCC) have led to prolonged patient survival, the high costs of the drugs place a heavy burden on both patients and society. The objectives of this study were to examine the treatment regimens used as first-line systemic treatment for patients with advanced HCC in Japan and to estimate the treatment costs per regimen. METHODS: For this study, we aggregated the data of patients who had received first-line systemic treatment for advanced HCC between July 2021 and June 2022...
June 7, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38843876/real-world-treatment-trends-for-patients-with-advanced-prostate-cancer-and-renal-cell-carcinoma-and-their-cost-a-survey-in-japan
#20
JOURNAL ARTICLE
Takahiro Osawa, Keita Sasaki, Ryunosuke Machida, Takashi Matsumoto, Yoshiyuki Matsui, Hiroshi Kitamura, Hiroyuki Nishiyama
BACKGROUND: Advanced (Stage IV) prostate and renal cancer have poor prognosis, and several therapies have been developed, but many are very costly. This study investigated drug regimens used in patients with untreated Stage IV prostate cancer and renal cell carcinoma and calculated the monthly cost of each. METHODS: We surveyed first-line drugs administered to patients with untreated Stage IV prostate cancer and renal cancer at Japan Clinical Oncology Group affiliated centers from April 2022 to March 2023...
June 7, 2024: Japanese Journal of Clinical Oncology
journal
journal
22718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.